Mutya Harsch
2023
In 2023, Mutya Harsch earned a total compensation of $1.1M as Chief Legal Officer, General Counsel and Secretary at VYNE Therapeutics, a 72% increase compared to previous year.
Compensation breakdown
| Bonus | $168,869 |
|---|---|
| Non-Equity Incentive Plan | $253,302 |
| Option Awards | $139,375 |
| Salary | $382,594 |
| Stock Awards | $168,750 |
| Other | $13,200 |
| Total | $1,126,090 |
Harsch received $382.6K in salary, accounting for 34% of the total pay in 2023.
Harsch also received $168.9K in bonus, $253.3K in non-equity incentive plan, $139.4K in option awards, $168.8K in stock awards and $13.2K in other compensation.
Rankings
In 2023, Mutya Harsch's compensation ranked 1,070th out of 2,918 executives tracked by ExecPay. In other words, Harsch earned more than 63.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,070 out of 2,918 | 63rd |
Division Manufacturing | 639 out of 1,608 | 60th |
Major group Chemicals And Allied Products | 436 out of 901 | 52nd |
Industry group Drugs | 425 out of 864 | 51st |
Industry Pharmaceutical Preparations | 290 out of 622 | 53rd |
Source: SEC filing on November 12, 2024.
Harsch's colleagues
We found two more compensation records of executives who worked with Mutya Harsch at VYNE Therapeutics in 2023.
News
VYNE Therapeutics CEO David Domzalski's 2023 pay jumps 110% to $2.7M
November 12, 2024
VYNE Therapeutics CEO David Domzalski's 2022 pay falls 73% to $1.3M
November 13, 2023
VYNE Therapeutics CEO David Domzalski's 2021 pay jumps 69% to $4.9M
June 17, 2022
VYNE Therapeutics CEO David Domzalski receives $2.9M in 2020
June 7, 2021